PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|May 23, 2016
Sanofi Loses Three Top Execs in Reshuffle
May 23, 2016.
Advertisement
Three of Sanofi's (Paris, France) top executives are leaving the company as its "2020 strategic roadmap" gets under way.
Pascale Witz, executive vice president of diabetes and cardiovascular, Carsten Hellmann, executive vice president of Merial, Sanofi’s animal health division, and Suresh Kumar, executive vice president of external affairs, have announced their intention to leave the company.
Hellmann has accepted a position as president and CEO of ALK (Horsholm, Denmark).
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
FDA Launches Rare Disease Framework Initiative
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5